W-GenZD-003:ReframeStudy
ARandomizedControlledTrialoftheFeasibilityandAcceptabilityofW-GenZDversusCBT-liteteletherapyforAdolescentsseekingMentalHealthServices
[STUDY_ID_REMOVED]
Version5.0
May312023

WoebotHealthVersion5.0W-GenZD-00331May2023
ConfidentialityStatement
TheinformationinthisprotocolisconfidentialandproprietaryinformationofWoebotHealth.Itisprovidedtoyouasasite,Investigatororconsultantforreviewby[CONTACT_10825],yourstaff,andotherapplicableregulatorybodies.AcceptanceofthisdocumentconstitutesagreementthatyouwillnotdisclosetheinformationcontainedhereintootherswithoutwrittenauthorizationfromtheSponsororinawaythatisinconsistentwithcontractuallanguage.
CONFIDENTIAL2
WoebotHealthVersion5.0W-GenZD-00331May2023
ProtocolVersionandAmendmentTracking
VersionNumber/AmendmentApprovalDate
1.003/31/2022
2.006/02/2022
3.006/14/2022
4.010/27/2022
5.05/31/2023
CONFIDENTIAL3
WoebotHealthVersion5.0W-GenZD-00331May2023
TableofContents
ConfidentialityStatement2
ProtocolVersionandAmendmentTracking3
TableofContents4
Table1.ScheduleofEvents7
ProtocolSynopsis9
Introduction12
1.1Background12
1.2ClinicalExperiencewithWoebot13
1.2.1RandomizedControlledTrial(RCT)ofanEarlyPrototypeofW-GenZDin18-28yearolds13
1.3Rationale13
2.Objectives14
3.StudyPopulation15
3.1SelectionofStudyPopulation15
3.1.1InclusionCriteria15
3.1.2ExclusionCriteria16
3.2ScreenFailures16
3.3WithdrawalofParticipantsfromtheStudy16
3.3.1ViolationofStudyPlan16
4.StudyDesign16
Figure1.Participantflowthroughstudy18
4.1TreatmentArms19
4.1.1W-GenZDMobileApplication19
4.1.2CBT-LiteTeletherapyGroups19
5.StudyAssessmentsandProcedures20
5.1DemographicQuestions20
5.2PsychiatricHistory20
5.3CHKDBriefClinicalNeedsAssessment20
CONFIDENTIAL4
WoebotHealthVersion5.0W-GenZD-00331May2023
5.4ClinicalOutcomes20
5.5WorkingAlliance21
5.6AcceptabilityandFeasibility21
5.7ParentalCheck-Ins22
5.8UnscheduledTelephoneVisit:SafetyResponse22
5.9ParticipantandParent/GuardianExitInterview22
6.SafetyNetProtocol(SNP)22
7.ConcomitantMedicationandTherapy23
8.RiskandBenefitAssessment23
8.1Risks23
8.1.1MisunderstandingtheCapabilitiesoftheApplication23
8.1.2DataBreach23
8.1.3PotentialUpsetduetoSurveyQuestions24
8.2Benefits24
9.StatisticalAnalysis24
9.1InterimReport25
10.AdverseEventReportingandFollow-Up25
10.1Definitions25
10.2Assessment26
10.2.1TimeFrame26
10.2.2CausalityRating26
10.2.3SeverityofADE26
10.3Reporting26
11.StudyKeyPersonnel26
CHKDPrincipalInvestigator:MaryMargaretGleason,M.D.,FAAP26
WoebotLiaison:EmilChiauzzi,Ph.D.27
WoebotLiaison:AthenaRobinson,Ph.D.27
CHKDSub-Investigator:CarlPetersen,D.O.27
CHKDCo-Investigator:NicoleWells,Ph.D.27
CONFIDENTIAL5
WoebotHealthVersion5.0W-GenZD-00331May2023
References28
Appendix1.ParentalCheck-InGuidance31
Appendix2.UnscheduledTelephoneVisit:SafetyResponseFollow-Up32
CONFIDENTIAL6
WoebotHealthVersion5.0W-GenZD-00331May2023
Table1.ScheduleofEvents
VisitWeeks/DaysScreeningPeriodTreatmentPeriodFollow-UpPeriod
ScreeningDay-7to-1BaselineDay0Visit2Day5(+2)Visit3/Week2Day14(+6)Visit4/Week4(EOT)Day28(+6)Visit5/Week6Day42(+6)Visit6Week8(EOS)Day56(+6)
InformedConsent/AssentXDemographicsc,d XPsychiatricHistoryc,d XPrior&ConcomitantMedications/Therapyd XXCHKDBriefClinicalNeedsAssessmentInformationd XEligibilityConfirmation(Inclusion/Exclusion)XRandomizationXDownloadStudyApplicationa XPHQ-8bXXXXGAD-7bXXXMFQbXXXWAI-SRbXXCSQ-8bXSatisfactionQuestionnaireaXUPRIbXAppEngagementMetrics(W-GenZDonly)XWeeklyteletherapyGroupAttendance(CBT-liteonly)dX
ParentalCheck-Ins(Telephonic)XXXXSNP/SafetyResponseeXHealthcareUtilizationc,dXAssessmentofAE/SAEsXXXXTerminationofW-GenZDandTeletherapyAccessXParticipantandParent/GuardianExitInterviewsfX
CONFIDENTIAL7
WoebotHealthVersion5.0W-GenZD-00331May2023
aW-GenZDparticipan tsonly,bSelf-ReportClinic alAssessmen t(adolescen t),cParent/Guar dianQues tionnair e,dCollect edfromCHKDsystem,eASNPorSafetyeventwilltriggeranunscheduledvisitfromICFtoEOS,seesection5.6,fOptionalstudyprocedur e;EOS=EndofStudy;EOT=EndofTreatmen t;SNP=Sa fetyNetProtocol
CONFIDENTIAL8
WoebotHealthVersion5.0W-GenZD-00331May2023
ProtocolSynopsis
StudyDeviceW-GenZD
ProtocolNumber:W-GenZD-003
ProtocolTitle:ARandomizedControlledTrialoftheFeasibilityandAcceptabilityofW-GenZDversusCBT-liteteletherapyforAdolescentsseekingMentalHealthServices
MainCriteriaforInclusion:Inclusion1.HavecompletedtriageatCHKDandhavebeendeemedappropriateforthelow-intensityinterventiontrack,givenpresentingproblem(s)ofdepressiveoranxietysymptoms2.Adolescent13-17yearsofage,inclusive3.U.S.Resident4.Bothadolescentparticipantandparent/guardianareabletoreadandwriteinEnglish5.Ownorhaveregularaccesstoasmartphone(AndroidoriOSsmartphonewitharecent,supportedoperatingsystem),thatcanreceiveSMSmessages,andreliableWi-Fiaccessorsufficientdatatoengagewithassignedtreatmentconditionforthedurationofthestudy6.Ifcurrentlyprescribedantidepressantmedications(e.g.escitalopram/Lexapro,fluoxetine/Prozac),antipsychoticmedications(e.g.aripi[INVESTIGATOR_4253],asenapi[INVESTIGATOR_050],olanzapi[INVESTIGATOR_050],paliperidone,quetiapi[INVESTIGATOR_050],risperidone),orstimulants(e.g.amphetamine/Adderall,Methylphenidate/Ritalin)andalphaagonists(e.g.atomoxetine/Strattera,Guanfacine/Intuniv)theyareataregular,stabledoseforatleast60daysatscreening7.Notcurrentlyactivelyengagedispsychotherapy8.Availableandcommittedtoengagewiththeprogramandcompleteassessmentsfora8-weekduration.9.Familyiswillingandabletoengageindiscussionofsafetyplanningintheeventofsuicidalsymptoms
CONFIDENTIAL9
WoebotHealthVersion5.0W-GenZD-00331May2023
Exclusion1.Lifetimediagnosisofapsychoticdisorder(includingschizophreniaorschizoaffectivedisorder)2.Lifetimediagnosisofbipolardisorder3.Lifetimediagnosisofautismspectrumdisorderorpervasivedevelopmentaldisorder(e.g.autism,Aspergersyndrome,Rett’ssyndrome)4.Currentdiagnosisofdevelopmentaldelayorintellectualdisability5.Suicidalideationwithaplanorintentorasuicidalattemptwithinthepast12months6.Historyof(a)drugand/oralcoholabusewithinthepast12months7.Currentuseofbenzodiazepi[INVESTIGATOR_1651](e.g.lorazepam,clonazepam,alprazolam,diazepam,triazolam)orcertainsleepaids(zolpi[INVESTIGATOR_6730],eszopi[INVESTIGATOR_11123],zaleplon)8.PreviousWoebotapplicationuse9.Enrollmentofmorethanonememberofthesamehousehold
StudyPrimaryObjective:WhatisthefeasibilityandacceptabilityofW-GenZDamongagroupofadolescentsandwhohavebeenscreenedandtriagedintolow-intensitytreatmentwithinCHKD?
StudyDesign:ThisstudywillbearandomizedcontrolledtrialofW-GenZDversusfcptonThetrialwillconsistof3primaryphases:Screening/Baseline,Treatment,andaFollow-upperiod.
TreatmentRegimen:W-GenZD:5-10minutesofdailyuserecommendedTeletherapyCBTGroups:1group/weekoftreatmentperiod
DurationofStudyParticipation:8weeks
NumberofParticipants:260participants
NumberofSites:1
PrimaryEndpoints:PrimaryFeasibilityandAcceptabilityoutcomesat4-weeks:
●UsageRatingProfileIntervention(URPI)-FeasibilityandURPI-Acceptability
●ClientSatisfactionQuestionnaire(CSQ-8)Additionalfeasibilityandacceptabilitymetrics:
CONFIDENTIAL10
WoebotHealthVersion5.0W-GenZD-00331May2023
●Appengagementmetrics(W-GenZDcondition)
●Content/Programsatisfactionratings(bothconditions)
●Groupattendance(CBT-liteteletherapycondition)Qualitativefindingsabouttheparticipantexperience,basedoninterviewswithaself-selectedsubsetofparticipants(adolescentandparent/guardian)
SecondaryEndpoints:
●PatientHealthQuestionnaireforTeens(PHQ-8)totalscore
●GeneralizedAnxietyDisorderQuestionnaire(GAD-7)
●MoodandFeelingQuestionnaire(MFQ)
TertiaryEndpoint:
●WorkingAllianceInventory-SR(WAI-SR)
ExploratoryEndpoints:
●Toobserveanddescribetheutilizationandoutcomesofthesafetyproceduresutilizedwithinthisstudy(SafetyNetProtocol,AE/SAEsanddevicerelatedness)
●Pre-periodandstudy-periodhealthcareutilizationdata.Thiswillinclude:
○Diagnosis(e.g.,ICDcode)andservicerendered(e.g.,CPTcode)
○EmergencyDepartmentutilization
○Primarycareutilization(e.g.,primarycarewellvisitandsickvisitappointment)
○Behavioral-healthrelatedutilization(psychiatry,psychology,othertherapi[INVESTIGATOR_541],etc)
○Psychiatricmedicationprescriptions
○Socialdeterminantsofhealthinformation(e.g.,foodandhousinginsecurityandsocialworkutilization)
○Comorbiditydata(i.e.,anyadditionalbehavioralhealthorphysicalhealthdiagnoses)
○ProblemList
○Anyrelevantlifetimepsychiatricassessments(e.g.,Vanderbilt,PHQ)
InterimReport:Readoutofcompletebaselinesampledescriptivestats(demographics,enrollmentdata,etc)andbaselinescoresofmeasures
CONFIDENTIAL11
WoebotHealthVersion5.0W-GenZD-00331May2023
1.Introduction
1.1BackgroundAdolescenceisauniqueandcriticalperiodofneurologicaldevelopment.Thebrainwillneverbeassensitivetorewardnorasplasticasitisduringadolescence[1].Itisalsothepeaktimefortheonsetofmostmentalillnesses[2].Mentalillnessesthatemergebeforeadulthoodcarrya10-foldhighercostthanthosethatemergeinadulthood[3].Withmentalillnessbeingthelargestandmostcostlyproblemtotheglobaleconomy[4]anddepressionspecificallybeingtheleadingcauseofdisabilityworldwide[5],thepublichealthimpactsarestaggering,yetpersistentlyincreasing,especiallyamongadolescents[6].Adolescenceisaveryvulnerabledevelopmentallifestage,inwhich50%oflifetimecasesofmentalillnessbeginby[CONTACT_466103]14,and75%by[CONTACT_466103]24[7].Depressiononsetinadolescencealsoconfershighriskforchronicdepressionrecurrenceaswellasotherpsychiatricsequelae[8,9].
TheAmericanPsychologicalAssociation’s(APA)[10],AmericanAcademyofPediatrics(AAP)[8],AmericanAcademyofChildandAdolescentPsychiatry(AACP),andtheNationalInstitutesofClinicalExcellence’s(NICE)[11]agreethatswiftandearlyinterventionofdepressioninadolescenceisacriticalpartofthestandardofcareforthispopulation,withallrecommendingroutinescreeningfordepression,particularlyinprimarycaresettings[8].Standardofcaretreatmentrecommendationsacrosstheboardincludepsychotherapyand/orpharmacotherapy,withAPA,AAPandNICEunanimouslyrecommendingcognitivebehavioraltherapy(CBT)andinterpersonaltherapyforadolescents(IPT-A)asthemostevidence-basedpsychotherapeuticoptions.Datasuggestthatcombiningpsychotherapyandanantidepressantmedication,particularlyformorecomplicatedorseverepresentations,mayhavebetteroutcomesthaneithertreatmentalone[12,13].Additionally,supportintheformofpsychoeducationandcasemanagement,aswellasinvolvementoffamilyandschoolthroughoutthetreatmentperiodisalsorecommended[8,14,15].
Inpractice,therearebarrierstoimplementingtheserecommendationsconsistentlyandthus,asmanyastwooutofthreeadolescentswithdepressiondonotreceiveanytreatment[13].ThereareonlytwoFDA-approvedpsychopharmacologicaloptionsforadolescentMDD,compoundedby[CONTACT_466104]-qualityempi[INVESTIGATOR_466084].Critically,lackofaccessisconsistentlyatreatmentbarrierformanyadolescents,especiallyaccesstocliniciansskilledinhigh-qualitypsychotherapyand/orpharmacotherapy.Thislongstandingnationalshortageofchildandadolescentspecialtytrainedproviders[13]oftenleavesthecomplexmanagementofadolescentdepressionintheoverburdenedhandsofprimarycareproviders.Inaddition,manyfamiliesarereluctanttoconsiderantidepressantmedicationsasfirst-linetreatmentforadolescents[16],preferringpsychotherapy[17].Yet,researchshowsthatrecommendedpsychotherapi[INVESTIGATOR_466085][18,19].Persistentbarrierstousepertaintoaccess,costandstigma[11,20],withthelatterdiscouragingadolescentsfromseekinghelp.Additionalproblemsinreal-worldpracticeincludeincompleteuseofscreeningtoolsevenwhenrecommendedattheorganizationallevelwithinapediatriccarenetwork[21],limitedguidanceonhowaclinicianshouldusethoseroutineassessmentstoinformtreatmentdecisions[22]andconcerningracialdisparitiesinratesoftreatmentandfollow-up[23].
Clearly,earlyandsuccessfulinterventioniscrucial,andyettherehavebeensurprisinglyfewtherapeuticapproachesspecificallydesignedforadolescents.Upto75%ofyoungpeoplewillnevergetthecarethattheyneed[24]andearlydropoutiscommonamongthosethatdo[25],suggestingthatthestructureandsystemsoftraditionalclinicalsettingsareillfittedtoadolescentlives.Inshort,access,broadlydefined,remainsthemostsignificantbarriertomentalhealthcareforyoungpeople.
CONFIDENTIAL12
WoebotHealthVersion5.0W-GenZD-00331May2023
Undoubtedlytechnologymustbecomepartofthesolution,aspartofanecosystemofmentalhealthservices.However,presentlytherearenoFDA-approvedmobilemedicaldevicesforthetreatmentofmajordepressioninadolescence.
1.2ClinicalExperiencewithWoebotWoebotisanautomatedrelationalagentbasedonthemostresearchedandscientificallyvalidatedpsychotherapi[INVESTIGATOR_014],primarilyCBT,andaccessibleviaaniOSandAndroidapplication.Theuserexperienceiscenteredaroundmoodtrackingandgoal-oriented,tailoredconversations.UsersbecomefamiliarwithWoebotasafriendly,helpfulcharacterthatisexplicitlynotahuman,noratherapi[INVESTIGATOR_541].Woebothasbeendesignedwithapersonalitytofacilitateaworkingallianceovertime.Dailypush-notificationspromptuserstocheck-inwithWoebot.Uponopeningtheapp,Woebotasksuserswhattheyaredoing(context)andhowtheyarefeeling(mood).Usingproprietarynaturallanguageprocessing(NLP)andartificialintelligence(AI),Woebotisabletounderstandusersinanorganic,familiarwayandleadthemappropriatelythroughaprogramthatispersonalizedeachday,inreal-time,totheuser'sneeds.
1.2.1RandomizedControlledTrial(RCT)ofanEarlyPrototypeofW-GenZDin18-28yearoldsPurpose:Toevaluatethefeasibility,acceptability,andpreliminaryefficacyofW-GenZDamongacollege-basedsample(N=70)inanRCTcomparinganearlyprototypeofW-GenZDtoaninformation-onlycontrolgroup.
Methods:Participantsages18-28years(N=70)whoself-identifiedasexperiencingsymptomsofdepressionandanxietywererandomizedtoreceiveWoebotorane-bookondepressionpublishedby[CONTACT_466105].Outcomeswereassessedat2-weeksend-of-treatment.Thestudywasapprovedby[CONTACT_466106](JMIR)[26].Thestudywaspoweredforthefull18-28agerange.Apost-hocsubgroupanalysiswasalsoperformedamongthoseparticipantsaged18-21years(n=26)tocharacterizeclinicaloutcomesforthisrelevantagegroupspecifically.
KeyResults:Inthebroadercohortofallparticipantsages18-28years,thoseintheWoebotgroupsignificantly(F=6.5;p=.01)reducedtheirsymptomsofdepressionoverthestudyperiodasmeasuredby[CONTACT_466107](PHQ-9),relativetothoseinthecontrolgroup[26].Participantsengagedwiththedeviceanaverageof12.14times(SD=2.23;median=12;range8-18)overthe2-weekstudyperiod.Asitrelatesspecificallytothesubgroupofinterest,37%ofparticipants(n=26/70)wereages18-21years.Intent-to-treatanalysisindicatedthatWoebotparticipantsages18-21yearsexperiencedareductioninsymptomsofdepressionasmeasuredby[CONTACT_466108]-9(meanreduction=1.7,SD(4.2)),andinsymptomsofanxietyasmeasuredby[CONTACT_466109](GAD-7)scale(meanreduction=1.7,SD(3.2))at2-weeks,ascomparedtobaseline.Within-subjecteffectsizesonbothmeasuresweresmalltomedium(Cohen’sd=.27and.31forPHQ-9andGAD-7,respectively);neitherofthesedifferenceswasstatisticallysignificant(t=-1.9,p=.09andt=-1.4,p=0.19,respectively)at2-weeks,relativetobaseline,duethelimitedsamplesizeastheoriginalstudywaspoweredforthefull18-28range.However,thesubgroupresultsshowatrendthatisconsistentwiththeoverallresults.
Conclusion:RCTresultsindicatedthatW-GenZDwasafeasible,effective,andengagingwaytodigitallydeliverCBTtoparticipantsself-identifyingashavingsymptomsofdepressionoranxiety,intheadolescentpopulationages18-28.Resultsinthe18-21subgroupwereconsistentwiththoseinthelargerstudy,butwerenotstatisticallysignificantsincethestudywasoriginallypoweredforthelargergroup.
CONFIDENTIAL13
WoebotHealthVersion5.0W-GenZD-00331May2023
1.3RationaleInrecentyears,therehasbeenanexplosionofinterestanddevelopmentoftechnologicalsolutionstoeithersupplementexistingmentalhealthtreatmentsorexpandaccesstoqualitymentalhealthservices.Thisdevelopmentwasmatchedby[CONTACT_466110]70%showinginterestinusingmobileapplications(apps)toself-monitorandself-managetheirmentalhealth[1].Internetinterventionsforanxietyanddepressionhavesignificantempi[INVESTIGATOR_290983][2]withoutcomescomparabletotherapi[INVESTIGATOR_541]-deliveredcognitivebehavioraltherapy(CBT)[3-4].Yet,despi[INVESTIGATOR_466086],theyarecharacterizedby[CONTACT_466111].Onereviewfoundamedianminimalcompletionrate(usuallydefinedascompletionof~4sessions)of56%[5].
Anotherproblemisthatalmostalloftheresearchonmobileappswasconductedonappsthatarenotcommerciallyavailable.Forexample,onesystematicreviewof5,464abstractsidentifiedjust5appsthathadsupportingevidencefromrandomizedcontrolledtrials,andnoneofthemwereavailablecommercially[6].Incontrast,appsthatwerecommerciallyavailabletypi[INVESTIGATOR_466087]/oracommitmenttodemonstrateoutcomes.
Conversationalagents,orchatbots,aresoftwareprogramsthatusenaturallanguageasinputsandoutputsinsteadof,forinstance,menucommands(e.g.,File/Save
As
…
)orgraphicalinputs(e.g.,clickingonanicontoopenanapp).RecentadvancementsinvoicerecognitionhavegivenrisetotheemergenceofmanyconversationalagentssuchasApple’sSiriorAmazon’sAlexa.Interactinginthiswayappearstobeamorenaturalmediumthroughwhichindividualsengagewithtechnology.Peoplerespondandconversewithnonhumanagentsinwaysthatmirroremotionalandsocialdiscoursedynamicswhendiscussingbehavioralhealth[7].
Moreover,evidence-basedin-persontherapi[INVESTIGATOR_466088],traditionallyassignclientsopportunitiestopracticetherapyskillsoutsideofsessions,commonlyreferredtoastherapyhomework.Historically,it’softenprovendifficulttoengageCBTclientsintheirhomeworkonaregularbasis.Conversationalinterfacesredefinetheentireconceptoftherapyhomework;theirabilitytobeavailableintheactualmomentofneed,regardlessoftimeofdayordayofweek,allowsclientstoengagewiththeirtherapyskillsin-vivo,whenitmattersmost.
Children’sHospi[INVESTIGATOR_466089]’sDaughters(CHKD)isa206-bed,freestandingchildren'shospi[INVESTIGATOR_466090]5,000admissionstothehospi[INVESTIGATOR_466091].TheCHKDmentalhealthprogramisorganizedasasteppedcaremodelinwhichpatientsaretriagedintoeitherloworhigh-intensitytracksdependingontheseverityofsymptoms,treatmenthistory,andclinicalpresentation.Duetothedemandforadolescentmentalhealthservices,thewaittimetoconnectwithprovidersiscurrentlyaround3months.Duringthiswaitingperiod,CHKDoffersseveralteletherapygroupstoadolescentsandtheirfamiliesseekingservicesasasupportthatcanbeutilizeduntilthereisavailability.
ThisprotocolaimstodemonstratethatWoebot,specificallyW-GenZD,isaviableoptionforthistypeofhealthcareecosystem.
2.ObjectivesPrimaryAim:WhatisthefeasibilityandacceptabilityofW-GenZDamongagroupofadolescentsandwhohavebeenscreenedandtriagedintolow-intensitytreatmentwithinCHKD?
●PrimaryFeasibilityandAcceptabilityoutcomesat4-weeks:
oUsageRatingProfileIntervention(URPI)-FeasibilityandURPI-Acceptability
CONFIDENTIAL14
WoebotHealthVersion5.0W-GenZD-00331May2023
oClientSatisfactionQuestionnaire(CSQ-8)
●Additionalfeasibilityandacceptabilitymetrics:
oAppengagementmetrics(W-GenZDcondition)
oContent/Programsatisfactionratings(bothconditions)
oGroupattendance(CBT-liteteletherapycondition)
●Qualitativefindingsabouttheparticipantexperience,basedoninterviewswithaself-selectedsubsetofparticipants(adolescentandparent/guardian)
SecondaryAim:WhatisthepreliminarycomparativeefficacyofW-GenZDandCBT-litetelehealthzoomgroupstomanagemoodconcernsat4-weeksendoftreatment(EOT),relativetobaseline?
●Secondaryoutcomes:
oPatientHealthQuestionnaireforTeens(PHQ-8)totalscore
TertiaryAim:InvestigatepotentialbetweengroupdifferencesonWorkingAlliance.
●Tertiaryoutcomes:
oWorkingAllianceInventory-SR(WAI-SR)
oGeneralizedAnxietyDisorderQuestionnaire(GAD-7)
oMoodandFeelingQuestionnaire(MFQ)
ExploratoryAim:Toobserveanddescribetheutilizationandoutcomesofthesafetyproceduresutilizedwithinthisstudy(SafetyNetProtocol,AE/SAEsanddevicerelatedness).Todescribethesamplepopulationwithrespecttohealthcareutilization,socialdeterminantsofhealth,andcomorbiditydataforpre-studyandduring-study(treatmentandfollow-up)periodsandexamineassociationsbetweenthesefactorsandstudyclinical,alliance,engagementandsatisfactionoutcomes.
3.StudyPopulation
3.1SelectionofStudyPopulationParticipantsarechildrenreferredtotheCHKDmentalhealthprogramandareeligibleforthelow-intensityinterventiontrack.Approximately30adolescentsaretriagedintothislow-intensitytrackperweek.Inordertobeeligibleforthelow-intensitytrack,adolescentsmustnotmeetoneormoreofthefollowingcriteria:havehadsuicidalideationwithinthelast2weeksorbeacurrentrisktoself/others,psychoticpresentation,meetcriteriaforanactiveeatingdisorder,historyofmania,substanceusedisorderistheprimaryclinicalproblem,isatimminentriskofexpulsion,oriscurrentlyprescribed4ormorepsychotropi[INVESTIGATOR_114075].
Aminimumof260participants(approximately130participants/arm)willbeenrolled.Ifparticipantsmeetallofthefollowinginclusioncriteriaandnoneoftheexclusioncriteria,theywillberandomlyassignedtostudytreatment.
3.1.1InclusionCriteriaInordertobeeligibletoparticipateinthisstudy,anindividualmustmeetallofthefollowingcriteria:
1.HavebeenreferredtoCHKDMentalHealthProgramanddeemedappropriateforthelow-intensityinterventiontrack,givenpresentingproblem(s)ofdepressiveoranxietysymptoms2.Adolescent13-17yearsofage,inclusive3.U.S.Resident
CONFIDENTIAL15
WoebotHealthVersion5.0W-GenZD-00331May2023
4.Bothadolescentparticipantandparent/guardianareabletoreadandwriteinEnglish5.Ownorhaveregularaccesstoasmartphone(AndroidoriOSsmartphonewitharecent,supportedoperatingsystem),thatcanreceiveSMSmessages,andreliableWi-Fiaccessorsufficientdatatoengagewithassignedtreatmentconditionforthedurationofthestudy6.Ifcurrentlyprescribedantidepressantmedications(e.g.escitalopram/Lexapro,fluoxetine/Prozac),antipsychoticmedications(e.g.aripi[INVESTIGATOR_4253],asenapi[INVESTIGATOR_050],olanzapi[INVESTIGATOR_050],paliperidone,quetiapi[INVESTIGATOR_050],risperidone),orstimulants(e.g.amphetamine/Adderall,Methylphenidate/Ritalin)andalphaagonists(e.g.atomoxetine/Strattera,Guanfacine/Intuniv)theyareataregular,stabledoseforatleast60daysatscreening7.Notcurrentlyactivelyengagedinpsychotherapy8.Availableandcommittedtoengagewiththeprogramandcompleteassessmentsfora8-weekduration.9.Familyiswillingandabletoengageindiscussionofsafetyplanningintheeventofsuicidalsymptoms
3.1.2ExclusionCriteriaAnindividualwhomeetsanyofthefollowingcriteriawillbeexcludedfromparticipationinthisstudy:
1.Lifetimediagnosisofapsychoticdisorder(includingschizophreniaorschizoaffectivedisorder)2.Lifetimediagnosisofbipolardisorder3.Lifetimediagnosisofautismspectrumdisorderorpervasivedevelopmentaldisorder(e.g.autism,Aspergersyndrome,Rett’ssyndrome)4.Currentdiagnosisofdevelopmentaldelayorintellectualdisability5.Suicidalideationwithaplanorintentorasuicidalattemptwithinthepast12months6.Historyofdiagnosisof(a)drugand/oralcoholabusewithinthepast12months7.Currentuseofbenzodiazepi[INVESTIGATOR_1651](e.g.lorazepam,clonazepam,alprazolam,diazepam,triazolam)orcertainsleepaids(zolpi[INVESTIGATOR_6730],eszopi[INVESTIGATOR_11123],zaleplon)8.PreviousWoebotapplicationuse9.Enrollmentofmorethanonememberofthesamehousehold.
3.2ScreenFailuresParticipantswhosignstudyassent/consentanddonotmeetinclusioncriteriaatScreening,willbeconsideredaScreenFailure.ParticipantswhoscreenfailwillreturntotheclinicalcarepathwayatCHKD.Re-screenswillnotbepermittedinthisstudy.
3.3WithdrawalofParticipan tsfromtheStudyIfaparticipantdecidestowithdrawconsentfromthestudy,theywillberemovedfromallfuturestudyactivities.Inaddition,aparticipantmaybewithdrawnby[CONTACT_466112],orforadministrativeand/orothersafetyreasons.ThoserandomizedintotheW-GenZDconditionwillberemovedfromthestudyappandprogramifwithdrawn.Alldatacollectedpriortowithdrawalmaybeusedindescriptivesummariesand/oranalyses.
3.3.1ViolationofStudyPlanParticipantsthatdonotcompleteregistrationfortheW-GenZDapplicationorwhodonotattendateletherapygroupwithinthefirstweekfollowingrandomizationwillnotberemovedfromthestudyforfailuretoaccessthestudyintervention.Participantswillremaininthestudyandwillcontinuetoreceiveinvitationstocompletesurveyassessments.Dependingonrandomizedcondition,thoseintheCBT-Litegroupmayattendtheremainingsessions(2-4)andthoseintheW-GenZDgroupmaydownloadtheappandprogramthedurationofthe4-weekinterventionperiod.Allparticipantsrandomizedtothisprotocol,regardlessofparticipationorwithdrawalstatus,willbeincludedintheintent-to-treatanalysis(seesection9.0).
CONFIDENTIAL16
WoebotHealthVersion5.0W-GenZD-00331May2023
4.StudyDesignThisstudywillbearandomizedcontrolledtrialofW-GenZDversusCBT-liteteletherapygroups.Thetrialwillconsistof3primaryphases:Screening/Baseline,Treatment,andaFollow-upperiod.
AlladolescentsreferredtotheCHKDMentalHealthProgramareprovidedanorientationabouttheclinicalcareprogramandparticipateinabriefclinicaltriageassessmenttoassessneededlevelofcare.Ingeneral,informationaboutthestudyandconsenttocontact[CONTACT_466113].Aspartofrecruitmentefforts,CHKDmayprovidefamilieswithtokensofengagement(e.g.,stressballs).Basedonthebriefclinicaltriageassessment,iftheadolescentisappropriateforthelow-intensityinterventiontrack,studystaffwillre-introducethestudyduringthetelephoneinterviewandassessthefamily’s(adolescentandparent/guardian)interestinparticipating.Researchstaffwillfollowupwiththosewhoexpressedinterest,presentthestudy,obtaininformedconsentandassent,facilitateassessmentcompletion,andassessinclusion/exclusioncriteria.
Adolescentswhodonotmeeteligibilitycriteriawillbethankedfortheirinterestandwillingnesstovolunteer,andwillreturntotheroutineclinicalcarepathwayatCHKD.
Adolescentswhomeetinclusioncriteriaaftercompletingthescreeningandbaselinequestionnaireswillberandomized1:1tothetreatmentgroups.Participantswhoarerandomizedwillenterthe4-weektreatmentperiodwheretheywillengageintheassignedgrouptreatmentandcompleteassessmentsatstudyday5,week2,andatendoftreatment,week4.Atweek4,studyapplicationaccessandparticipationintheteletherapygroupswillendandparticipantswillcompleteafollow-upassessmentattheendofstudy,week8.
CONFIDENTIAL17
WoebotHealthVersion5.0W-GenZD-00331May2023
Figure1.Participantflowthroughstudy
CONFIDENTIAL18

WoebotHealthVersion5.0W-GenZD-00331May2023
4.1TreatmentArms
4.1.1W-GenZDMobileApplicationW-GenZDisamobileapplicationprogramthatdeliversevidence-basedtherapyforthesymptomsofmild-moderatedepressionandanxietyinadolescentsinbrief“conversations”withafullyautomatedrelationalagentcalledWoebot.Itisabrief,self-guided4-weekinterventionthatdrawsfromCBT,IPT-Aandelementsofdialecticalbehaviortherapy(DBT),dependingonthepresentingsituation,tohelptheadolescentdevelopemotionregulationskillsinthecontextoftheireverydaylife.Inthisway,themobileapplicationisdesignedtobetargeted,relevant,andintegratedintothelivedexperienceofadolescents,capableofdeliveringtheappropriatetechniquefortheproblemathand,atthetimeofneed.W-GenZDwasadaptedfromanddiffersfromthebroaderWoebotplatforminkeyways.
1.UniqueCheck-InFlow2.UniqueOnboarding3.UniqueContentModulesa.PsychoeducationalLessons:Newtopi[INVESTIGATOR_466092].PsychotherapeuticTools:NewtoolsforCommunicationAnalysisandConversationRole-Play,aswellasRelationshipDevelopmentc.BehavioralHealthProblemAreas:expandedSleep,Communication,Procrastination,Loneliness,andAnxietyareas.
W-GenZDwasbuiltfromasynthesisof:
1.Human-centereddesignprocess,tounderstandtheneedsandlivedexperienceofadolescentswithdepression,2.Interviewswithcliniciansexpertinadolescentmentalhealth,whichhighlightedandunderpi[INVESTIGATOR_466093],and3.Criticalanalysisoftheliteratureoncurrentstandardofcare,effectiveapproaches,modalities,andproblemstobesolved.
ParticipantswillgainaccesstothestudyapplicationoncerandomizedthroughoutWeek4(EOT)andareencouragedtousetheappforaminimumof5minutesperdayduringthetreatmentperiod.
4.1.2CBT-LiteTeletherapyGroupsTheCBT-LightteletherapygroupsaimtoprovidesupporttoadolescentsseekingtreatmentaftertheyhavebeentriagedintoCHKD’slow-intensitytrack.Intheclinicalsetting,CHKDoffersCBT-liteteletherapygroupsforyouthwithlowintensitysymptomswhoarewaitingforindividualcare,asdescribedabove.Theresearch-specificgroupsareabrief,4-weekinterventionheldonceweeklyforanhour,andlimitedtothoseparticipatinginthisprotocol.Enrolledparticipantsrandomizedtogroupareofferedthegroupthatbestfitstheirschedule.Anassignedstudyclinicianwillfacilitateeachteletherapygroupwithupto10adolescentsineachsession.Eachgroupbeginswithorientationandreviewinggrouprules,individualcheck-inswitheachparticipant(ratingstresslevelandhopefulness),followedby[CONTACT_466114].
Groupswillbeconductedonanopen-enrollment,rollingtopi[INVESTIGATOR_466094],allowingforparticipantstojointhenextavailablesessionfollowingrandomizationandcompleteall4sessionsduringtheirstudytreatmentperiod.SessionsaredesignedtodrawfromelementsofCBTandthe4topi[INVESTIGATOR_466095]:Buildingacopi[INVESTIGATOR_466096],Acceptyourfeelings,Challengenegativethoughts,andProblemsolving.
CONFIDENTIAL19
WoebotHealthVersion5.0W-GenZD-00331May2023
Fidelitytogroupprocessismonitoredby[CONTACT_105]-clinicianstudyteammember.
ParticipantsrandomizedtotheCBT-LiteTeletherapyGroupwillbeofferedaccesstotheWoebotLIFEappattheendofstudy.
5.StudyAssessmentsandProceduresAllassessments,andtheircorrespondingadministrationpoints,arelistedinTable1.
5.1Demogr aphicQuestionsAtscreening,basicdemographicinformationincludinggenderandsexualidentity,racialbackground,andlevelofeducationwillbecollected.
5.2PsychiatricHistoryParticipants’parent/guardianwillbeaskedatscreeningabouttheirchild’shistoryofpsychiatricillnesses,specificallythoseexclusionarytothisstudy,andforanypriororconcomitantmedicationsandtherapy.Informationaroundcurrentandpastyearsuicidalityandsubstanceusewillalsobecollected.
5.3CHKDBriefClinicalNeedsAssessmen tIfaparticipantisdeemedeligibleforthelow-intensityCHKDtrackandconsentsforthisresearchstudy,thefollowingdatafromtheCHKDtriageandbrief-clinicalneedsassessmentwillbecollectedatscreeningtohelpestablisheligibility:
●Preliminarydiagnosis(givenpresentingproblem(s)ofdepressiveoranxietysymptoms)
●Low-intensitytrackeligibility,by[CONTACT_466115]:
○Suicidalideationwithinthelast2weeksorbeacurrentrisktoself/others
○Psychoticpresentation
○Meetscriteriaforaneatingdisorder
○Historyofmania
○Substanceusedisorder(astheprimaryclinicalproblem)
○Imminentriskofexpulsion
○Currentlyprescribed4ormorepsychotropi[INVESTIGATOR_466097]-clinicalneedsassessmentdatawillbecollectedfromCHKD,asitbecomesavailablebasedoncompletionby[CONTACT_466116],andmayincludethefollowing:
●Triageassessmentscores:
○AskSuicideScreeningQuestions(ASQ)
○SafeEnvironmentforEveryKid(SEEK)ParentQuestionnaire
○StrengthsandDifficultiesQuestionnaire(bothparents/guardianandadolescent)
○PediatricQualityofLife(PQL)(bothparents/guardianandadolescent)
5.4ClinicalOutcomesThefollowingclinicaloutcomeswillbecollectedviasurveyplatformby[CONTACT_466117]-report.
ThePatientHealthQuestionnaire(PHQ-8)The8-itemPHQ,anabbreviatedversionofthePHQ-9,thePHQ-8,willbeusedtoassessmoodandanxietysymptomsrespectively.ThePHQ-9isawidelyusedself-reportmeasure,withdemonstratedreliabilityandsensitivitytoclinical
CONFIDENTIAL20
WoebotHealthVersion5.0W-GenZD-00331May2023
change.ThePHQ-8excludesanitemassessingsuicidality[34].
GeneralizedAnxietyDisorder(GAD-7)TheGAD-7itemscaleisabriefself-reporttooltoassessthefrequencyandseverityofanxiousthoughtsandbehaviorsoverthepast2weeks.Itisawidelyutilized,reliable,andvalidmeasureofanxiety[35].
MoodandFeelingsQuestionnaire(MFQ)TheMFQshort-versionisachildself-reportassessmentconsistingofaseriesof13descriptivephrasesrelatedtotheparticipant’srecentfeelingsandbehaviors.Respondentsreflectonwhetherthephrasesare“true”,“sometimestrue”,or“nottrue”ofthesubject’sfeelingsandbehaviorsduringthepasttwo-weekperiod[36].
5.5WorkingAllianceWorkingAllianceInventory(WAI-SR)TheWAI-SRisameasureoftherapeuticbondandconsistsofacompositescoreandthreesubscales;Bond,Goal,andTask.Bondmeasuresthestrengthofthetherapeuticrelationshipbetweentheclientandtherapi[INVESTIGATOR_541].Goalmeasuresagreementonthegoaloftheoveralltherapeuticprogrambetweentheclientandtherapi[INVESTIGATOR_541].Taskmeasuresagreementbetweentheclientandtherapi[INVESTIGATOR_541],regardingthespecificactivitiesneededforatherapeuticchangetooccursuchasdoinganexercisetoameliorateaspecificsymptom[37].Thepresentstudyutilizedthevalidated12-itemShortRevisedversion(WAI-SR)withminorchangestolanguage,replacing“therapi[INVESTIGATOR_541]”withthenameoftheassignedtreatmentgroup.
5.6AcceptabilityandFeasibilityTheClientSatisfactionQuestionnaire(CSQ-8)TheCSQ-8isan8-itemmeasureusedtoassessclient’ssatisfactionwithtreatmentona4-pointscale(1=“verydissatisfied”to4=“verysatisfied”).Examplequestionsinclude,“howwouldyouratethequalityofserviceyoureceived?”and“didyougetthekindofserviceyouwanted?”Totalsumsrangefrom8-32,withhighscoresindicatinggreatersatisfactionwithW-GenZD.TheCSQ-8hasbeenwidelydisseminatedandconsideredbothvalidandreliable
(
αranges=.83-.93)[38].
SatisfactionQuestionnaireParticipantswillbeasked3open-endedquestionsaboutwhattheyfoundmosthelpfulabouttheirtreatmentarm,whatwouldmakeitbetter,andifthereisanyotherfeedbacktheywouldliketoshare.
UsageRatingProfileIntervention(URPI)URPI-FeasibilityandURPI-Acceptabilityareboth6-itemsubscalesfromtheURP-InterventionRevised(URP-IR)scale.Responsesrangefrom1="slightlydisagree"to6="stronglyagree".Scoresareaverages,withgreaterscoresindicatinggreaterinterventionfeasibilityoracceptability.TheURPI-Feasibilityinquiresaboutfactorsthatimpacttreatmentusage(i.e.,interventionquality)andhasacceptablereliability,internalconsistency,anddiscriminantvalidity.TheURPI-Acceptabilityinquiresaboutinterventionacceptability.Ithasdemonstratedhighreliabilityandinternalconsistency[39].
SafetyProceduresUtilizationdata,includingfrequency,type,andoutcomes,willbecollectedthroughoutthisprotocoltoreportonincidentsofSafetyNetProtocoltriggersandtheoccurrenceandrelatednessofAE/SAEs.
AppEngagement
CONFIDENTIAL21
WoebotHealthVersion5.0W-GenZD-00331May2023
Datacharacterizingmobileapplicationuse,includingdaysinappandcontentengagement,willbecollectedthroughouttreatment(4-weeks)forparticipantsrandomizedtotheW-GenZDtreatmentarm.
GroupAttendanceGroupattendancewillbekeptby[CONTACT_466118]/studycoordinatorthroughoutthestudyandprovidedthroughtheEDCfromrandomizationthroughtheendoftreatment(4-weeks)forthoserandomizedtotheCBT-liteteletherapytreatmentarm.
HealthcareUtilizationDataregardingaparticipant’shealthcareresourceutilization(HCRU),socialdeterminantsofhealthandcomorbiditydatawillbecollectedthroughoutthepre-study,treatmentandfollow-upperiods.ParticipantswillhavevariouslengthsofengagementwithintheCHKDsystem,thereforepre-studyHCRUdatawillbecollectedfromthetimeoffirstengagementthroughenteringthestudyanduntilendofstudy.ThiswillincludeCPTandICDcodes,diagnoses(e.g.,EHRProblemListdata),treatmentsincludingmedicationsrelatedtopediatricvisitsintheCHKDsystem,(emergencydepartmentvisits,pediatricandmentalhealthcareofficevisits,outpatientbehavioralhealthcarevisits,andmedicationsavailableforservicesprovidedintheCHKDhealthsystem)andanyrelevantlifetimepsychiatricassessments(e.g.,Vanderbilt,PHQ).
5.7ParentalCheck-InsAtweeks2,4,6,and8astudypersonnelwillconductatelephonicvisitwiththeparticipant’sparent/guardian.DuringthesecallsinformationregardingAE/SAEsandconcomitantmedicationswillbecollected.Thesecallswillalsoserveasanopportunitytoaddressanytrouble-shootingaroundtheuseoftheapplicationorattendancetotheCBT-liteteletherapygroup.SeeAppendix1.forfullguidelinesforthesecheck-ins.
5.8UnscheduledTelephoneVisit:SafetyResponseIfatanytimefollowingconsent,throughtheendofstudy,thatanadolescenthasasafetyevent,definedasariskoractualharmtoselforothers,qualifiedstudypersonnelwillconductanimmediateunscheduledprotocolvisit(telephonecontact).Studypersonnelwilllearnoftheseeventsthroughseveralmethods:1.AparticipantintheGen-ZDtreatmentgroupconfirmsacrisisinthemobileapp(SeeSection6.)2.ACBT-liteteletherapygroupfacilitatorlearnsofriskduringgroupsession3.Iscontact[CONTACT_466119]/guardian
Duringtheunscheduledtelephonevisit,theclinicianwillassesssuicidality,thoughtsofself-harmorharmtoothers,includingplanandintent,aswellasprotectivemeasuresandasafetyplan.ForthefullSNPResponseproceduresandguidelines,refertoAppendix2.
5.9Participan tandParent/GuardianExitInterviewThegoalofthepost-studyinterviewsistoidentifyopportunitiesforproductimprovement.Thisincludesdiscussionoftheparticipant'smentalhealthjourney&typi[INVESTIGATOR_466098],aswellastheirexperiencewiththeproduct.Duringstudyconsent,participantswillbepresentedwiththeopportunitytoconsenttothisoptionalstudyprocedure.Followingstudycompletionat8-weeks,ifconsentwasgrantedtobecontact[CONTACT_466120],astudyrepresentativewillreachoutandschedulewithparticipantsbasedonavailability.Effortswillbemadetointerviewparticipantsequallyfrombothtreatmentarmsofthestudy.Duetoavailabilityofinterviewappointmentsandpotentialnumberofinterestedparticipants,notallwhoexpressinterestinthisoptionalprocedurewillbecontact[INVESTIGATOR_530].
CONFIDENTIAL22
WoebotHealthVersion5.0W-GenZD-00331May2023
6.SafetyNetProtocol(SNP)Woebot’s(W-GenZD)naturallanguageprocessingalgorithmwasdesignedtodetectlanguagethatsuggestsausermaybeinimminentcrisis.Specifically,itwilldetectifauserinputs,viafreeresponsetextentry,aphraseorword(s)thatmatchesana-priorideterminedandthoroughlistofsuchphrasesandword(s)thatmaybeusedinimminentcrisissituations.Afterthealgorithmdetectsthesewords,itwillinquireifitisindeedacrisissituation.Iftheusersaysyes,theapplicationwillnotifytheparticipantthattheon-callstudyclinicianwillbereachingouttoprovidesupportandassesssafety.
Afternotificationofthesafetyresponsefollow-up,W-GenZDwilloffertohelpthatpersoninthemomentwiththeirupsettingthoughts.Thisisclinicallyrelevantbecausesuicidalthoughtsarethoughtsthatcanbeaddressedthroughcognitivetherapytechniques.Ourvaluehereinistosupportandprovidein-vivoskillstosomeonewhoseeksassistanceinchangingtheiremotionsandthoughtsinthemoment.
Onceacrisishasbeenconfirmed,W-GenZDwillsendaHIPAAcompliantalert(viaJabber,Spok,orothermutuallyagreeduponcommunicationschannel)todesignatedclinicalstaffwhowillbeoncalltoprovide24/7coverageofthesealertmessages.Thisindividual,whowillbeonthestudyteam,willbeembeddedintheCHKDsystemofcare,andthereforeinapositiontotriagetheindividual,engagedirectlywiththeparticipanttoensuretheirsafetyandwellbeing,and/orrefertoemergencyservicesasnecessary.Triagedecisionsresultingfromtheclinicalalertswillbeseparatelylogged,inHIPAAcomplaintfashion,forpurposesofimprovingtheSafetyNetProtocol.
7.ConcomitantMedicationandTherapyWhilemanyadolescentswhoareseekingservicesmaynotbeprescribedpsychotropi[INVESTIGATOR_114075],thosethatareconnectedtotreatmentwillbeallowedtoparticipateinthisstudyandcontinuetheircurrentregimenifthefollowinginclusion/exclusioncriteriaismet:
1.Ifcurrentlyprescribedantidepressantmedications(e.g.escitalopram/Lexapro,fluoxetine/Prozac),antipsychoticmedications(e.g.aripi[INVESTIGATOR_4253],asenapi[INVESTIGATOR_050],olanzapi[INVESTIGATOR_050],paliperidone,quetiapi[INVESTIGATOR_050],risperidone),orstimulants(e.g.amphetamine/Adderall,Methylphenidate/Ritalin)andalphaagonists(e.g.atomoxetine/Strattera,Guanfacine/Intuniv),theyareataregular,stabledoseforatleast60daysatscreeningwithnoplanstochangemedication/dosethroughoutthestudy2.Isnotcurrentlyusingbenzodiazepi[INVESTIGATOR_1651](e.g.lorazepam,clonazepam,alprazolam,diazepam,triazolam)orcertainsleepaids(zolpi[INVESTIGATOR_6730],eszopi[INVESTIGATOR_11123],zaleplon)
Useofconcomitantmedicationsthroughoutthestudywillbecollectedatbaseline,week4EOTandweek8EOS.
8.RiskandBenefitAssessment
8.1RisksGiventhattheresearchaimstoenrollparticipantsintoalow-riskinterventionthatreplacesapassivewaitlist,wedonotanticipatethatparticipationinthestudywillbeassociatedwithelevatedrisk.Participationinthestudyisindependenttopharmacologicaltreatmentsbeingutilizedby[CONTACT_466121].Theoverallevaluationofriskisthatitislow.
8.1.1MisunderstandingtheCapabilitiesoftheApplicationW-GenZDisnotintendedtobeacrisisservice,howevergiventhenatureofthetargetedpopulationandexperienceofdepression,thereisthepotentialparticipantsmaymisunderstandthelimitationsoftheapp.To
CONFIDENTIAL23
WoebotHealthVersion5.0W-GenZD-00331May2023
mitigatethisrisk,thestudywillprovideclearinformationonthecapabilitiesoftheapp,intendeduse,andlimitationsoftheSOSfeatureatconsent/assent,randomization,andkeypointsthroughout.Additionally,whenasafetyeventistriggered,anon-callCHKDclinicianwillreceiveanimmediatenotificationandfollow-upwiththeparticipantasoutlinedintheSafetyNetProtocol.
8.1.2DataBreachAllstudydata,fromparticipantself-reportandCHKDstudypersonnel,aregatheredoneitheraHIPAA-compliantwebplatformthatresidesbehindWoebotHealthsecurityfirewallsorviaaHIPAA-compliantsurveyplatform,thusactualriskfromdatabreachforstudydataislow.Researchmaterialobtainedfromhumansubjectswillinvolvebehavioralandpsychologicalassessmentsincludingself-reportquestionnaires.AlldataobtainedviaWoebotwillbeencryptedandstoredonAmazonWebServices(AWS)and/orGoogleCloudPlatform;WoebotHealthdatagatheringandstorageproceduresarecompliantwithbothHIPAAandtheEuropeanUnion'sGeneralDataProtectionRegulation.Onlymembersoftheresearchteamwillhaveaccesstoidentifiablestudydata.De-identifieddatawillbeaccessibletotheproductdevelopmentteam(designers,userresearchers,andproductmanagers)aswellastheresearchteam.
8.1.3PotentialUpsetduetoStudyProceduresForeseeableriskstoparticipantsincludethepossibilitythatsomeassessmentquestionsand/ortreatmentproceduresmaybeupsettingtoparticipants.Experiencewithsimilarpopulationshasindicatedthattheriskofemotionalupsetduringtheassessmentsislowandifitoccurred,theupsetwouldlikelybetemporaryandnotbeseriousinnature.Suchriskswillbeminimizedby[CONTACT_466122].Participantswillalsobeinformedthattheymaywithdrawfromthestudyatanytimeandifrequested,appropriateresourceswillbeprovided.
Thereisalsoapotentialriskofdistressattheendoftheassignedstudyintervention(s).Participantsareinformedduringtheconsentprocess,andareremindedatrandomization,parentalcheck-insatweeks2and4,andattheendofthesurveysatweek4thattheywillnolongerhaveaccesstothestudyintervention(s)afterweek4.Returntocareandotherresourcesareprovidedatweek6andtheendofthestudyatweek8orearlierifdeemednecessaryby[CONTACT_466123].
Participantscanrefuseandwithdrawfromparticipationatanytime.Iftheywithdrawconsentfromthestudy,theywillnolongerhaveaccesstothestudytreatments.
8.2BenefitsWhenevaluatingtherisksandbenefitsoftheproposedstudy,itisbelievedthatrisksarerelativelyminimalwhencomparedtothepotentialtherapeuticbenefitsthatsubjectsarelikelytoreceive.ThepossiblebenefitsofreceivingWoebotorparticipatingintheCBT-liteteletherapygroupsincludepotentiallyimprovingmood(anxiety,stress,and/ordepression),acquiringpracticalpsychotherapeuticskills(fromcognitivebehavioraltherapy,dialecticalbehaviortherapy,andmindfulness),andreceivingpsychoeducationaboutmentalhealth.
Participantswhoimprovemoodmayderiveadditionalbenefitsshouldsaidmoodimprovementsbeassociatedwithotherpsychologicalimprovementssuchasinterpersonaloroccupationalfunctioning.StudyoftheeffectivenessoftheW-GenZDinterventionwillalsobenefitsocietymoregenerallyby[CONTACT_466124].
9.StatisticalAnalysisThisstudywasdesignedtoassessthefeasibilityofdeliveringW-GenZDasanoptionforadolescentsages13-17yearstriagedintoalowintensitytrackformentalhealthcarewhileonawaitinglistfordefinitivetreatment.
PrimaryAim:WhatisthefeasibilityandacceptabilityoftheW-GenZDamongagroupofadolescentsandwhohavebeenscreenedandtriagedintolow-intensitytreatmentwithinCHKD?
CONFIDENTIAL24
WoebotHealthVersion5.0W-GenZD-00331May2023
Hypothesis:W-GenZDwillbeacceptableandfeasible.
PrimaryEndpoints:Feasibilityandacceptabilitymetricsincluding:
●Studyenrollmentrates
●URPI-Feasibility;UPRI-Acceptability{12items}
●ClientSatisfactionQuestionnaire(CSQ-8){8items}
●Appengagementmetrics{Woebotcondition}
○Measure:Appengagement,includingnumberofmessagessenttoWoebotby[CONTACT_466125]
○Measure:Contentandprogramsatisfactionratings,includingdatacollectedinapp(e.g.,moduleratings)AnalysisPlan:Statisticalanalysiswillbedescriptive.Continuousvariableswillbesummarizedusingtablesofdescriptivestatistics:numberofparticipantswithrecordedobservations,mean,standarddeviation,median,firstquartile,thirdquartile,minimum,maximumandinterquartilerange(IQR).Studyenrollmentrateswillbereported.ForsubjectsintheWoebotconditiontheappengagementmeasureswillbesummarized.Similarly,thecontentandprogramsatisfactionratings,includingdatacollectedintheappwillbesummarized.Categoricalandordinalvariableswillbedescribedusingfrequenciesandpercentages..Theamountofmissingdatawillbesummarizedby[CONTACT_466126].
SecondaryAim:WhatisthepreliminarycomparativeefficacyofW-GenZDandCBT-litetelehealthzoomgroupstomanagemoodandanxietyconcerns?
Hypothesis:W-GenZDwillbenon-inferiortoCBT-litewithregardstothesecondaryendpointsat4-weeksend-of-treatment
SecondaryEndpoints:
●PHQ-8
AnalysisPlan:Toassessthesecondaryaimnon-inferioritytestswillbeused.Thesecondaryanalysiswillfocusonmeetingthesecondaryaimofaninitialtestofthenon-inferiorityofW-GenZDascomparedtoCBT-litetelehealthzoom,tomanagemoodconcerns.Anintent-to-treatanalysiswillbeusedwithparticipantsanalyzedasassignedtothetreatmentconditions.Mean,standarddeviation,median,firstquartile,thirdquartile,minimum,maximumandinterquartilerange(IQR)willbereportedforeachvariableateachtimepoint.Anon-inferiortestwillbeemployed.Themarginofclinicalsignificancefortheoutcomeswillbesetto2.Thesetestswillbeperformedforeachvariableusingtheendoftreatmenttimepoint.Inaddition,ameta-analysiswillbeperformedtoassesstheactivecontroleffectofthecbt-basedtelehealthinapediatricpopulation.FulldetailswillbespecifiedintheSAP.
TertiaryAim:Investigatepotentialbetweengroupdifferences..
TertiaryEndpoints:
●WorkingAllianceInventory-SR(WAI-SR)
●GAD-7
●MFQ
AnalysisPlan:ThetertiaryanalysiswillfocusonmeetingthetertiaryaimofaninitialtestofthepotentialbetweengroupdifferencesontheWAI-SR,GAD-7,andMFQ.Anintent-to-treatanalysiswillbeusedwithparticipantsanalyzedasassignedtotreatmentconditions.
CONFIDENTIAL25
WoebotHealthVersion5.0W-GenZD-00331May2023
ExploratoryAim:Toobserveanddescribeupontheutilizationandoutcomesofthesafetyproceduresutilizedwithinthisstudy(SafetyNetProtocol,AE/SAEsanddevicerelatedness).ForeachAE/SAEtype,andSafetyNetProtocol,nwillbereported.Toexplorehealthcareutilization,socialdeterminantsofhealth,andcomorbiditydataforpre-studyandduring-study(treatmentandfollow-up)periods.
ExploratoryEndpoints:
●SafetyNetProtocol,AE/SAEsanddevicerelatedness
●Pre-periodandstudy-periodhealthcareutilizationdata.Thiswillinclude:
○Diagnosis(e.g.,ICDcode)andservicerendered(e.g.,CPTcode)
○EmergencyDepartmentutilization
○Primarycareutilization(e.g.,primarycarewellvisitandsickvisitappointment)
○Behavioral-healthrelatedutilization(psychiatry,psychology,othertherapi[INVESTIGATOR_541],etc)
○Psychiatricmedicationprescriptions
○Socialdeterminantsofhealthinformation(e.g.,foodandhousinginsecurityandsocialworkutilization) 
○Comorbiditydata(i.e.,anyadditionalbehavioralhealthorphysicalhealthdiagnoses)
○ProblemList 
○Anyrelevantlifetimepsychiatricassessments(e.g,Vanderbilt,PHQ)
AnalysisPlan:Primarycareutilization,behavioralhealthcarevisitsutilization,psychiatricmedicationutilization,EmergencyDepartmentvisitsutilization,socialdeterminantsofhealth,comorbidityanddiagnosesdata,andpsychiatricscreeningswhererelevantwillbesummarizedusingdescriptivestatisticsforW-GenZDandCBT-litetelehealthzoomgroups.
9.1InterimReportReadoutofcompletebaselinesampledescriptivestatistics(demographics,enrollmentdata,etc)andbaselinescoresofmeasureswillbecompletedafterthelastpatentrandomizesintothestudy.
10.AdverseEventReportingandFollow-Up
10.1DefinitionsAdverseEvent(AE):Anyunfavorableandunintendedsign,symptom,ordiseasetemporallyassociatedwiththeuseofthestudydevice,whetherornotconsideredrelatedtotheproduct.
SeriousAdverseEvent(SAE):Anyadverseeventrequiringmedicaltreatmentorothermajorinterventions.
10.2AssessmentDuetothelow-riskprofileofthisstudy,adverseandseriousadverseeventsarenotanticipated.Theinvestigatorwillbealerttoanycomplaintsoradversereactionsthatariseandwilltakeappropriatestepstoalleviatethedifficultiesassoonaspossible.
10.2.1TimeFrameAnyeventobservedorreportedfromthetimeofrandomizationthroughthefinalstudyvisit(week8)willbecollected.
CONFIDENTIAL26
WoebotHealthVersion5.0W-GenZD-00331May2023
10.2.2CausalityRatingAnevent’srelatednesstotheinvestigationaldevicewillbedeterminedby[CONTACT_466127]:
Non-related:Thereisnoevidenceofanycausalrelationship.
Related:Thereisclearevidenceofacasualrelationshipbetweenthedeviceandevent;allotherexplanationshavebeenruledout.
10.2.3SeverityofADE
Mild:Awarenessofsign,symptom,orevent,buteasilytolerated.
Moderate:Discomfortenoughtocauseinterferencewithusualactivityandmaywarrantintervention.
Severe:Incapacitatingwithinabilitytodousualactivitiesorsignificantlyaffectsclinicalstatusandwarrantsintervention.
10.3ReportingThedesignatedstudyteamwillreportaneventtotheSponsorwithin24hoursoflearningofit.TheinvestigatorshouldmakeeveryattempttoobtainasmuchinformationaspossibleandmustassesstherelationshipoftheeventtothestudydeviceandcompletetheAE/SAEassessmentform.Itisunderstoodthatmoremaybelearnedabouttheeventaftertheinitialreportandthisinformationmayandshouldbeupdatedascollected.
Anyeventthatthesponsordeterminesis/arereportabletotheIRBwillbemadewithin5workingdaysofwhenthesponsormakesthatdetermination.Ifitshouldbedeterminedthataneventpresentsanunreasonablerisktoallparticipants,thestudyorpartsofthestudypresentingthatriskwillbeterminatedassoonaspossible.
11.StudyKeyPersonnel
CHKDPrincipalInvestigator:MaryMargaretGleason,M.D.,FAAPDr.Gleasonisapediatricianandchildandadolescentpsychiatrist.SheisDivisionDirectorofChildandAdolescentPsychiatryatEasternVirginiaMedicalSchoolandViceChiefofMentalHealthatChildren’sHospi[INVESTIGATOR_466089]’sDaughters(CHKD).AsPrincipalInvestigatoroftheproposedstudy,Dr.GleasonwillorganizeoverallresearchactivitiesandisresponsibleforexecutionoftheprotocolasoutlinedintheContractualAgreementbetweentheSponsor(WoebotHealth)andtheInstitution(CHKD).
WoebotLIaison:EmilChiauzzi,PhD.EmilChiauzzi,Ph.D.isWoebot’sDirectorofResearchandaclinicalpsychologistwithextensivedigitalhealthresearchexperience.AsCo-Investigatorofthisprotocol,hewillparticipateinprotocolplanning,studymonitoring,andreviewingdatafromthestudy.Ifthestudyproceedstomanuscriptpreparationforjournalsubmission,hewillparticipateasacoauthor.
WoebotLiaison:AthenaRobinson,Ph.D.AthenaRobinson,Ph.D.isWoebotHealth’sChiefClinicalOfficerandaclinicalpsychologistwithextensiveexperienceinclinicaloutcomesresearchandinterventionleadershiputilizingevidence-supportedtheoryandCONFIDENTIAL27
WoebotHealthVersion5.0W-GenZD-00331May2023
treatment.ShehasservedasPrincipalInvestigatorandCo-Investigatoronnumeroustrials.Dr.Robinsonwillplayanintegralroleinthisproject'sdevelopmentandwillmaintaininvolvementandoversightastheprojectenrollsparticipants.
CHKDCo-Investigator:NicoleWells,Ph.D.Dr.Wellsisalicensedpsychologistwithaspecializationinchildpsychology.Sheisanactiveclinicianandhasexperienceinresearch.Dr.Wellswillparticipateinplanningoftheresearchstudyandsupportdaytodayimplementationoftheproject.
CONFIDENTIAL28
WoebotHealthVersion5.0W-GenZD-00331May2023
References
1.GriffinA.AdolescentNeurologicalDevelopmentandImplicationsforHealthandWell-Being.Healthcare.2017;5(4).doi:10.3390/healthcare50400622.GieddJN,KeshavanM,PausT.Whydomanypsychiatricdisordersemergeduringadolescence?NatRevNeurosci.2008;9(12):947-957.doi:10.1038/nrn25133.Economicaspectsofmentalhealthinchildrenandadolescents.AccessedFebruary1,2021.https://www.euro.who.int/en/health-topi[INVESTIGATOR_1102]/Life-stages/child-and-adolescent-health/publications/2007/economic-aspects-of-mental-health-in-children-and-adolescents4.LynchFL,ClarkeGN.EstimatingtheEconomicBurdenofDepressioninChildrenandAdolescents.AmJPrevMed.2006;31(6):143-151.doi:10.1016/j.amepre.2006.07.0015.ReddyMS.Depression:TheDisorderandtheBurden.IndianJPsycholMed.2010;32(1):1-2.doi:10.4103/0253-7176.705106.WeinbergerAH,GbedemahM,MartinezAM,NashD,GaleaS,GoodwinRD.Trendsindepressionprevalenceinthe[LOCATION_003]from2005to2015:wideningdisparitiesinvulnerablegroups.PsycholMed.2018;48(8):1308-1315.doi:10.1017/S00332917170027817.KesslerRC,BerglundP,DemlerO,JinR,MerikangasKR,WaltersEE.Lifetimeprevalenceandage-of-onsetdistributionsofDSM-IVdisordersintheNationalComorbiditySurveyReplication.ArchGenPsychiatry.2005;62(6):593-602.doi:10.1001/archpsyc.62.6.5938.CheungAH,ZuckerbrotRA,JensenPS,LaraqueD,SteinREK,GLAD-PCSTEERINGGROUP.GuidelinesforAdolescentDepressioninPrimaryCare(GLAD-PC):PartII.TreatmentandOngoingManagement.Pediatrics.2018;141(3):e20174082.doi:10.1542/peds.2017-[ZIP_CODE].GliedS,Pi[INVESTIGATOR_466099].ConsequencesandCorrelatesofAdolescentDepression.ArchPediatrAdolescMed.2002;156(10):1009.doi:10.1001/archpedi.156.10.100910.AmericanPsychologicalAssociation.APAGuidelineForTheTreatmentOfDepression.PublishedonlineFebruary16,2019.https://www.apa.org/depression-guideline/guideline.pdf11.KretzschmarK,TyrollH,PavariniG,ManziniA,SinghI.CanYourPhoneBeYourTherapi[INVESTIGATOR_541]?YoungPeople’sEthicalPerspectivesontheUseofFullyAutomatedConversationalAgents(Chatbots)inMentalHealthSupport.BiomedInformInsights.2019;11.doi:10.1177/117822261982908312.NationalInstituteofMentalHealth.MajorDepression.AccessedJanuary28,2021.https://www.nimh.nih.gov/health/statistics/major-depression.shtml#part_15503113.ZuckerbrotRA,CheungA,JensenPS,SteinREK,LaraqueD,GroupG-PS.GuidelinesforAdolescentDepressioninPrimaryCare(GLAD-PC):PartI.PracticePreparation,Identification,Assessment,andInitialManagement.Pediatrics.2018;141(3).doi:10.1542/peds.2017-408114.BirmaherB,BrentD.PracticeParameterfortheAssessmentandTreatmentofChildrenandAdolescentsWithDepressiveDisorders.JAmAcadChildAdolescPsychiatry.2007;46(11):1503-1526.doi:10.1097/chi.0b013e318145ae1c15.SadockBJ,KaplanHI,SadockVA.Kaplan&Sadock’sSynopsisofPsychiatry:BehavioralSciences/ClinicalPsychiatry.10thed.WolterKluwer/Lippi[INVESTIGATOR_305958]&Wilkins;2007.16.SteinREK,ZitnerLE,JensenPS.Interventionsforadolescentdepressioninprimarycare.Pediatrics.2006;118(2):669-682.doi:10.1542/peds.2005-208617.AsarnowJR,JaycoxLH,DuanN,etal.Effectivenessofaqualityimprovementinterventionforadolescentdepressioninprimarycareclinics:arandomizedcontrolledtrial.JAMA.2005;293(3):311-319.doi:10.1001/jama.293.3.311
CONFIDENTIAL29
WoebotHealthVersion5.0W-GenZD-00331May2023
18.ShafranR,ClarkDM,FairburnCG,etal.Mindthegap:ImprovingthedisseminationofCBT.BehavResTher.2009;47(11):902-909.doi:10.1016/j.brat.2009.07.[ZIP_CODE].GarbuttJ,SterkelR,RueckerK,DoddS,SmithE,PlaxK.ReadyfortheChallengeofDepressionCareintheMedicalHome.ClinPediatr(Phila).2019;58(7):816-818.doi:10.1177/000992281983428020.FulmerR,JoerinA,GentileB,LakerinkL,RauwsM.UsingPsychologicalArtificialIntelligence(Tess)toRelieveSymptomsofDepressionandAnxiety:RandomizedControlledTrial.JMIRMentHealth.2018;5(4):e9782.doi:10.2196/mental.978221.FarleyAM,GallopRJ,BrooksES,GerdesM,BushML,YoungJF.IdentificationandManagementofAdolescentDepressioninaLargePediatricCareNetwork.JDevBehavPediatr.2020;41(2):85-94.doi:10.1097/DBP.000000000000075022.LiuFF,AdrianMC.IsTreatmentWorking?DetectingRealChangeintheTreatmentofChildandAdolescentDepression.JAmAcadChildAdolescPsychiatry.2019;58(12):1157-1164.doi:10.1016/j.jaac.2019.02.[ZIP_CODE].OlfsonM,GameroffMJ,MarcusSC,WaslickBD.OutpatienttreatmentofchildandadolescentdepressionintheUnitedStates.ArchGenPsychiatry.2003;60(12):1236-1242.doi:10.1001/archpsyc.60.12.123624.ThornicroftG.Mostpeoplewithmentalillnessarenottreated.LancetLondEngl.2007;370(9590):807-808.doi:10.1016/S0140-6736(07)[ZIP_CODE]-025.SchleiderJL,WeiszJR.LittleTreatments,PromisingEffects?Meta-AnalysisofSingle-SessionInterventionsfor YouthPsychiatricProblems.JAmAcadChildAdolescPsychiatry.2017;56(2):107-115.doi:10.1016/j.jaac.2016.11.[ZIP_CODE].FitzpatrickKK,DarcyA,VierhileM.DeliveringCognitiveBehaviorTherapytoYoungAdultsWithSymptomsofDepressionandAnxietyUsingaFullyAutomatedConversationalAgent(Woebot):ARandomizedControlledTrial.JMIRMentHealth.2017;4(2).doi:10.2196/mental.778527.TorousJ,ChanSR,TanSY-M,BehrensJ,MathewI,ConradEJ,etal.PatientSmartphoneOwnershipandInterestinMobileAppstoMonitorSymptomsofMentalHealthConditions:ASurveyinFourGeographicallyDistinctPsychiatricClinics.JMIRMentHealth.2014;1(1):e5.doi:10.2196/mental.4004
28.SpekV,CuijpersP,
Nyklí
č
ekI,RiperH,KeyzerJ,PopV.Internet-basedcognitivebehaviourtherapyforsymptomsofdepressionandanxiety:ameta-analysis.PsycholMed.2007Mar;37(3):319–28.doi:10.1017/S0033291706008944
29.BarakA,HenL,Boniel-NissimM,Shapi[INVESTIGATOR_466100].AComprehensiveReviewandaMeta-AnalysisoftheEffectivenessofInternet-BasedPsychotherapeuticInterventions.JTechnolHumServ.2008Jul3;26(2–4):109–60.doi:10.1080/15228830802094429
30.AnderssonG,CuijpersP.Internet-basedandothercomputerizedpsychologicaltreatmentsforadultdepression:ameta-analysis.CognBehavTher.2009;38(4):196–205.doi:10.1080/16506070903318960
31.DonkinL,HickieIB,ChristensenH,NaismithSL,NealB,CockayneNL,etal.RethinkingtheDose-ResponseRelationshipBetweenUsageandOutcomeinanOnlineInterventionforDepression:RandomizedControlledTrial.JMedInternetRes.2013;15(10):e231.PMC3806549
32.BakkerD,KazantzisN,RickwoodD,RickardN.MentalHealthSmartphoneApps:ReviewandEvidence-BasedRecommendationsforFutureDevelopments.JMIRMentHealth.2016;3(1):e7.doi:10.2196/mental.4984
33.LucasGM,GratchJ,KingA,MorencyL-P.It’sonlyacomputer:virtualhumansincreasewillingnesstodisclose.ComputHumanBehav.2014;37:94-100.doi:10.1016/j.chb.2014.04.[ZIP_CODE].KroenkeK,StrineTW,Spi[INVESTIGATOR_466101],WilliamsJB,BerryJT,MokdadAH.ThePHQ-8asameasureofcurrentdepressioninthegeneralpopulation.JAffectDisord.2009Apr;114(1-3):163-73.doi:10.1016/j.jad.2008.06.026.Epub2008Aug27.PMID:18752852.
CONFIDENTIAL30
WoebotHealthVersion5.0W-GenZD-00331May2023
35.Spi[INVESTIGATOR_466101],KroenkeK,WilliamsJBW,LöweB.Abriefmeasureforassessinggeneralizedanxietydisorder:theGAD-7.ArchInternMed.2006May22;166(10):1092–7.doi:10.1001/archinte.166.10.1092
36.Angold,A.,Costello,E.J.,Messer,S.C.,Pi[INVESTIGATOR_1321],A.,Winder,F.,&Silver,D.(1995).Developmentofashortquestionnaireforuseinepi[INVESTIGATOR_466102].InternationalJournalofMethodsinPsychiatricResearch,5,237-249.37.MunderT,WilmersF,LeonhartR,LinsterHW,BarthJ.WorkingAllianceInventory-ShortRevised(WAI-SR):psychometricpropertiesinoutpatientsandinpatients.ClinPsycholPsychother.Publishedonline2009:n/a-n/a.doi:10.1002/cpp.[ZIP_CODE].LarsenDL,AttkissonCC,HargreavesWA,NguyenTD.Assessmentofclient/patientsatisfaction:developmentofageneralscale.EvalProgramPlann.1979;2(3):197–207.doi:10.1016/0149-7189(79)[ZIP_CODE]-639.BrieschAM,ChafouleasSM,NeugebauerSR,Riley-TillmanTC.Assessinginfluencesoninterventionimplementation:RevisionoftheUsageRatingProfile-Intervention.JournalofSchoolPsychology.2013Feb1;51(1):81-96.doi:10.1016/j.jsp.2012.08.006
CONFIDENTIAL31
WoebotHealthVersion5.0W-GenZD-00331May2023
Appendix1.ParentalCheck-InGuidance
AtprotocolVisits3,4,5,and6(Weeks2,4,6,and8),studypersonnelwillconductatelephonevisitwiththeparticipant’sparent/guardian.
1.ConductanAE/SAEassessment2.Inquireiftherehavebeenanychangestotheparticipant’smedical/psychiatrichistoryorconcomitantmedication/therapy3.Addressanytechnologicaltrouble-shootingtheymaybeexperiencing(W-GenZDapplicationuseoraccessingtheCBT-liteteletherapygroups)4.Remindtheparent/guardianofnextvisitandexpectationsinthestudy
Onaverage,telephonevisitsshouldlastbetween5-15minutesdependingontheparent/guardianreport.
DatafromthesecallswillbecapturedintheEDCundertheappropriateweek’stelephonevisitform.
CONFIDENTIAL32
WoebotHealthVersion5.0W-GenZD-00331May2023
Appendix2.UnscheduledTelephoneVisit:SafetyResponseFollow-Up
IfasafetyriskisidentifiedduringagroupCBT-liteteletherapysession:
1.Requestthattheat-riskparticipantstayonaftergrouporarrangeanimmediatedirectcallifnecessary2.AdministertheASQandfullyevaluatetheparticipant’sself-harmorsuicidalideation/plan/intent,orharmtoothers3.Iftheparticipantisnotatimminentrisk,reviewprotectivemeasuresandasafetyplana.Ifanimminentriskisidentified,contact[CONTACT_466128]/guardianand/oremergencyservices4.Contact[CONTACT_321237]’sparent/guardianoridentifiedemergencycontact[CONTACT_466129]5.SubmittheUnscheduledVisit:SafetyResponsedatacollectionform
Ifyoureceiveanotificationthataparticipanthasconfirmedacrisisinthemobileapp:
1.Makeimmediateattemptstocontact[CONTACT_321237]’sparent/guardianoridentifiedemergencycontacta.3attemptswithin1hourshouldbemadei.Recommendedmethodisfirstby[CONTACT_466130],followedby[CONTACT_466131]2.Ifcontact[CONTACT_466132],sharethereasonforthecall,inquireabouttheparticipant’swhereaboutsandiftheyareavailabletospeakwiththecliniciana.Ifparticipantisavailable,administertheASQandfullyevaluatetheparticipant’sself-harmorsuicidalideation/plan/intent,orharmtoothersb.Reviewprotectivemeasuresandasafetyplanwiththeparticipantandthenwiththeparent/guardian3.Ifcontact[CONTACT_466133]/guardianoridentifiedemergencycontact,contact[CONTACT_466134]4.SubmittheUnscheduledVisit:SafetyResponsedatacollectionform
Ifaparent/guardian,identifiedemergencycontact[CONTACT_466135]:
1.Ifparticipantisavailable,administertheASQandfullyevaluatetheparticipant’sself-harmorsuicidalideation/plan/intent,orharmtoothersa.Ifnotanimminentrisk,reviewprotectivemeasuresandasafetyplanwiththeparticipantb.Ifanimminentriskisidentified,contact[CONTACT_466128]/guardianand/oremergencyservices2.Follow-upwiththeparent/guardianoridentifiedemergencycontact[CONTACT_466136]3.SubmittheUnscheduledVisit:SafetyResponsedatacollectionform
FollowinganyidentificationofanAdverseorSeriousAdverseEvent(AE/SAE)oracontact[CONTACT_466137],studycliniciansshouldcontinuetofollow-upwiththefamilyappropriatelyuntiltheeventhasbeendeterminedtoberesolved.ProperAE/SAEreportingtimeframesshouldbefollowed.
CONFIDENTIAL33